Predictive Oncology Inc. announced Predictive Oncology's Good Manufacturing Practices (GMP) lab, which opens the opportunity to help clients move from pre-clinical drug development to the investigational new drug (IND) qualification, including phase 1 clinical trials. The company has begun accepting orders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 USD | -6.67% |
|
-3.08% | -61.70% |
Jun. 04 | Predictive Oncology Inc. Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery | CI |
May. 28 | Top Premarket Gainers | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-61.70% | 5.17M | |
-6.01% | 180B | |
-0.87% | 107B | |
-4.86% | 67.04B | |
-8.28% | 45.26B | |
+13.07% | 45.73B | |
+4.45% | 41.86B | |
+21.56% | 31.49B | |
+13.46% | 24.77B | |
-4.50% | 24.5B |
- Stock Market
- Equities
- POAI Stock
- News Predictive Oncology Inc.
- Predictive Oncology Inc. Strengthens Offerings with GMP Lab